Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer

Savolitinib, a small-molecule inhibitor of the receptor tyrosine kinase mesenchymal-epithelial transition (MET) factor, was approved for the treatment of non-small cell lung cancer (NSCLC) by the China National Medical Products Administration in June 2021. Its safety for NSCLC treatment has been con...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Ye, Cao, Qing, Guo, Yongzheng, Liu, Xiang, Zhu, Xueling, Dai, Bohao, Zhu, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932794/
https://www.ncbi.nlm.nih.gov/pubmed/36817157
http://dx.doi.org/10.3389/fphar.2023.1089184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932794/
https://www.ncbi.nlm.nih.gov/pubmed/36817157
http://dx.doi.org/10.3389/fphar.2023.1089184

Ejemplares similares